Levetiracetam Abz (Levetiracetam)

Levetiracetam is an anticonvulsant used to control epileptic seizure activity.

• Partial seizures: reduces the frequency and severity of focal onset seizures, improving daily functioning in patients with epilepsy.
• Generalized tonic‑clonic seizures: helps prevent convulsive episodes and associated loss of consciousness, contributing to better seizure control in generalized epilepsy.
• Myoclonic seizures: decreases the occurrence of sudden, brief muscle jerks, aiding symptom management in patients with myoclonic epilepsy.
• Adjunct therapy: can be combined with other antiepileptic drugs to enhance overall seizure control and allow dose reduction of concomitant agents.

• Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilizing neuronal membranes. This interaction reduces excessive synaptic firing and neuronal excitability, thereby diminishing the propagation of epileptic discharges across the central nervous system. The precise downstream effects are not fully elucidated, but the overall result is a lowering of the threshold for seizure generation without significant interaction with G‑protein coupled receptors or ion channels.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness: sensation of lightheadedness or unsteadiness, often occurring shortly after dosing.
• Fatigue: feeling unusually tired or low energy, which may affect daily activities.
• Headache: mild to moderate head pain that can be intermittent.
• Irritability: mood changes including increased agitation or short‑tempered behavior.
• Nausea: mild stomach upset or queasiness, sometimes accompanied by loss of appetite.
• Somnolence: increased sleepiness or drowsiness during the day, potentially impacting alertness.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing that may require immediate medical attention.
• Mood or behavior changes: depression, suicidal thoughts, aggression, or severe anxiety that should be reported promptly.
• Blood abnormalities: low white blood cell count or platelet count, increasing risk of infection or bleeding.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: adjust dose in patients with reduced kidney function.
• Psychiatric history: monitor for mood changes or suicidal ideation.
• Concomitant CNS depressants: use caution as combined effects may increase sedation.
• Pregnancy: risk unknown; weigh benefits against potential fetal exposure.
• Elderly patients: start at lower dose and monitor for adverse effects.
• Hepatic impairment: no routine dose adjustment required, but monitor liver function tests periodically.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control and requiring dose reassessment.
• Phenobarbital: can lower levetiracetam concentrations, potentially compromising effectiveness and necessitating close monitoring.
• Phenytoin: may decrease levetiracetam exposure, requiring close monitoring and possible dose adjustment.
• Rifampin: induces hepatic enzymes that may lower levetiracetam levels, risking loss of